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Abstract  
Parthenolide (PTN), a selective nuclear factor kappa B (NF-κB) inhibitor, has been used extensively to inhibit 
NF-κB activation. The duration of the inhibitory effect of PTN on NF-κB in vivo remains unclear. This study was 
to determine whether a lipopolysaccharide (LPS) challenge 6, 12 and 24 h after the administration of PTN could 
activate NF-κB. Rats were devided into five groups. The rats in the PTN, PTN+LPS and DMSO groups were in-
jected intraperitoneally with PTN or DMSO. After 6, 12 or 24 h, LPS was administered in LPS and PTN+LPS 
groups. The expressions of NF-κB p50, IκBα and p-IκBα were inhibited in both PTN and PTN+LPS group at end 
of 6 and 12 h and no effects at 24 h. In summary, myocardial NF-κB expression occurs 1 h after the administration 
of LPS. PTN blocks this effect given at 6 h and no inhibitory effect 24 h after administration in vivo.
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INTRODUCTION
Nuclear factor-kappa B (NF-κB) participates in the 
regulation of multiple immediate early gene products 
involved in immune, acute phase and inflammatory 
responses, in addition to programmed cell death and 
cellular proliferation[1]. At present, NF-κB as a cen-
tral event leading to the activation of sepsis and sep-
tic shock can be activated by a variety of pathogens 
known to cause septic shock syndrome[2].
Parthenolide (PTN), an NF-κB inhibitor, is respon-
sible for many anti-inflammatory effects and has been 
used extensively in previous studies[3-8]. In vitro study 
has suggested that PTN can inhibit IKK and also di-
rectly inactivate NF-κB[4]. In addition, other studies 
have reported that PTN inhibits NF-κB activation in 
cultured cells and experimental models[5-8]. Evidence 
supports the concept that PTN can inhibit NF-κB ac-
tivation by selective inhibition of IKK activation and 
IκBα degradation; however, data regarding effective-
ness of PTN duration in vivo are currently unavailable.
Treating cells with lipopolysaccharide (LPS) re-
sults in the dissociation of cytoplasmic complexes 
containing NF-κB and the translocation of free NF-
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κB to the nucleus[9]. LPS is a primary inducer of in-
flammatory responses through the biosynthesis and 
release of a variety of inflammatory mediators via the 
mononuclear phagocyte system, which is involved in 
the immune inflammatory response, leading to sep-
sis and septic shock. NF-κB is a central mediator lead-
ing to sepsis and septic shock and can be activated by a 
variety of pathogens known to cause septic shock syn-
drome. The role of NF-κB activation in the pathophys-
iology of sepsis and the signal transduction pathways 
leading to NF-κB activation during sepsis has been 
intensively investigated[2]. NF-κB activity has been 
found to be markedly increased in every organ studied 
to date in both animal models of septic shock and hu-
mans with sepsis. The inhibition of NF-κB activation 
prevents multiple organ injury and improves survival 
in a rodent model of septic shock. Thus, NF-κB activa-
tion plays a central role in the pathophysiology of sep-
tic shock[2,10]. PTN is a selective NF-κB inhibitor and 
protects against septic shock syndrome by selective 
inhibition of IKK activation and IκBα degradation[8]. 
In the present study, we investigated the specific role 
of NF-κB translocation in rat myocardium after an 
LPS challenge and determined whether the admin-
istration of PTN as a NF-κB inhibitor 6, 12 and 24 h 
prior could inhibit this effect. 
MATERIALS AND METHODS
Grouping and experimental protocol
This study was approved by the Animal Care Com-
mittee of the Medical College of Soochow University, 
and all experiments were conducted in accordance 
with the guidelines for animal care of the National 
Institutes of Health. A total of 90 adult male Sprague-
Dawley rats (10-12 w, 250-350 g) were used in this 
study. Fig. 1 illustrates the treatment groups in our 
study. We randomly devided the rats into 5 groups (n 
= 6 in each group) at 6, 12 and 24 h after receiving in-
traperitoneally (i.p.) PTN, respectively: control (CON), 
PTN, DMSO, LPS and PTN+LPS. The rats in the 
PTN, PTN+LPS and DMSO groups were injected i.p. 
with PTN (500 μg/kg) or DMSO as indicated, while 
the rats in the other groups were injected i.p. with an 
equivalent amount of saline[11]. At 6, 12 and 24 h after 
PTN injection, LPS (12.5 mg/kg) was administered 
subcutaneously to the LPS and PTN+LPS groups[12], 
while the rats in the other groups were injected subcu-
taneously with an equivalent volume of saline. Hearts 
were collected 1 h after LPS injection. The rats were 
anesthetized with an i.p. injection of sodium pentobar-
bital (50 mg/kg) and anticoagulated with an i.p. injec-
tion of heparin (1,000 U/kg). Left ventricular samples 
were quickly excised, cut into five or six cross-sec-
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Fig. 1 Schematic illustration of the experimental pro-
tocol used in Western immunoblotting experiments. 
Rats were divided into five groups at 6, 12 and 24 h after re-
ceiving intraperitoneally PTN, respectively: control CON, PTN, 
DMSO, LPS and PTN+LPS. LPS was administered subcutane-
ously at 6, 12 and 24 h after PTN injection. For Western im-
munoblotting measurements, the tissue samples were obtained 
1 h after receiving LPS. PTN: parthenolide; DMSO: dimethyl-
sulfoxide; LPS: lipopolysaccharide; NS: physiological normal 
saline. 
tional slices of 2 mm thickness, snap frozen in liquid 
nitrogen and stored at -80°C for subsequent analysis.
Western blotting analysis of NF-κB p50, IκBα 
and p-IκBα expression levels
Western immunoblotting was performed as de-
scribed previously[13,14]. Briefly, frozen tissue samples 
were homogenized using a polytron homogenizer 
(Beyotime Institute of Biotechnology, Haimen, China) 
in ice-cold lysis buffer with the complete protease 
inhibitor phenylmethylsulfonyl fluoride. After cen-
trifugation at 15,000 g for 15 min at 4°C, total protein 
was isolated. The clarified supernatant was collected 
to quantify total protein expression. Protein concen-
trations were determined using an enhanced BCA 
protein assay kit (Beyotime Institute of Biotechnol-
ogy). Equivalent amounts (100 μg) of protein sam-
ples were mixed with Laemmli buffer and heated at 
100°C for 5 min, then separated by 5% to 10% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to nitrocellulose mem-
branes (Pall Corporation, East Hills, USA) at 100 
V for 1.5 h. The membranes were blocked with 5% 
nonfat dry milk in TBST (10 mmol/L Tris-HCl, pH 
7.5, 150 mmol/L NaCl, 0.05% Tween-20) for 1 h at 
room temperature and immunoblotted overnight at 
4°C with a rabbit polyclonal anti-NF-κB p50 anti-
body (Santa Cruz Biotechnology, Santa Cruz, USA), 
a rabbit polyclonal anti-phospho-IκBα antibody (Cell 
Signaling Co., Danvers, USA) or a mouse monoclonal 
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anti-phospho-IκBα antibody (Santa Cruz Biotech-
nology) diluted 1:500 in 5% nonfat dry milk buffer. 
Membranes were then washed three times in TBST 
and incubated with a peroxidase-labeled anti-rabbit or 
anti-mouse IgG secondary antibody diluted 1:5,000 in 
5% nonfat dry milk buffer (Cell Signaling Co.) for 1 h 
at room temperature. Membranes were washed three 
times in TBST before the antigen-antibody complexes 
were detected. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as a reference for quanti-
tative analysis. Specific antigen-antibody complexes 
were detected using an enhanced chemiluminescence 
system (ECL, Merck, Darmstadt, Germany). Pro-
tein densitometry was performed using Sigma Pro5.0 
(Sigma, Saint Louis, USA).
Statistical analysis
Data were shown as mean±SD. Statistical analyses 
were performed with SAS 8.1 software (SAS Institute 
Inc, Cary, USA). Differences between groups were 
evaluated using two-way analysis of variance, when 
appropriate, and the post hoc test used was the New-
man-Keuls test. All P values were two-tailed and a P 
value < 0.05 was considered significant.
RESULTS
Expression of NF-κB p50 protein
The NF-κB p50 protein at 6 h was up-regulated in 
the LPS group [(97±10)%, P < 0.05] in comparison 
with the CON group [(36±11)%], but there was no 
significant difference in the expression of NF-κB p50 
in the PTN, DMSO and PTN+LPS groups [(32±9)%, 
(37±12)% and (41±13)%, respectively] compared to 
the CON group (Fig. 2A). 
The NF-κB p50 protein at 12 h had no significant 
difference in the PTN and DMSO groups [(34±10)% 
and (36±19)%,  respectively] compared to the CON 
group [(37±14)%], but the NF-κB p50 protein 
was up-regulated in the LPS and PTN+LPS groups 
[(104±4)% and (87±17)% respectively, P < 0.05] 
compared to the CON group. However, the up-regu-
lated amplitude of the PTN+LPS group was smaller 
than that of the LPS group (P < 0.05, Fig. 2B).
Western blot analysis showed that the NF-κB p50 
protein at 24 h was up-regulated in the LPS and 
PTN+LPS groups [(103±17)% and (108±20)%, re-
spectively, P < 0.05] 1 h after subcutaneous injection 
of LPS compared to the CON group [(27±10)%], but 
there was no significant difference in the expression 
of NF-κB p50 protein in the PTN and DMSO groups 
[(40±15)% and (43±14)%, respectively] compared 
to the CON group (Fig. 2C).
Expression of IκBα protein
At 6 h, there were no changes in IκBα expression in 
the PTN, DMSO and PTN+LPS groups [(68±10)%, 
(71±12)%, and (65±14)% respectively] compared 
to the CON group [(69±9)%], but the IκBα protein 
expression of the LPS group [(39±7)%, P < 0.05] 
was down-regulated compared to the CON group (Fig. 
3A).
At 12 h, the Western blotting analysis showed that 
the IκBα protein expression in the PTN and DMSO 
groups had no significant difference [(66±8)% and 
Fig. 2 Representative effect of PTN on NF-κB p50 in 
the presence or absence of LPS. A, B and C stand for 
the expression of NF-κB p50 at 6, 12 and 24 h after receiv-
ing intraperitoneally PTN, respectively. Data are shown as the 
mean±SD, with n = 6 in each group. GAPDH: glyceralde-
hyde-3-phosphate dehydrogenase; PTN: parthenolide; DMSO: 
dimethylsulfoxide; LPS: lipopolysaccharide.
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(63±10)%, respectively] compared to the CON group 
[(69±12)%], but in the LPS and PTN+LPS groups 
IκBα was decreased [(38±11)% and (52±7)%, re-
spectively, P < 0.05] compared to the CON group. 
However, the amplitude in the PTN+LPS group was 
smaller than that of the LPS group (P < 0.05, Fig. 3B).
At 24 h, Western blotting analysis revealed that 
there was no significant difference in IκBα expres-
sion in the PTN and DMSO groups [(85±9)% and 
(82±5)%, respectively, P > 0.05] compared to the 
CON group (80±11)% 1 h after injecting LPS sub-
cutaneously. IκBα levels in the cytoplasmic frac-
tion of the heart, however, decreased in the LPS and 
PTN+LPS groups [(38±5)% and (37±5)%, respec-
tively, P < 0.05, Fig. 3C].
Expression of p-IκBα protein
At 6 h, the Western blotting analysis showed that 
p-IκBα protein was up-regulated in the LPS group 
[(100±28)%, P < 0.05] compared to the CON group 
[(41±16)%], but there was no evident change of 
the expression of p-IκBα in the PTN, DMSO and 
PTN+LPS groups [(45±21)%, (49±24)% and 
(51±16)%, respectively] compared to the CON group 
(Fig. 4A). 
At 12 h, the expression of p-IκBα had no signifi-
cant difference in the CON, PTN and DMSO groups 
[(41±15)%, (45±19)% and (48±20)%, respec-
tively], but the p-IκBα protein was up-regulated in 
the LPS and PTN+LPS groups [(102±16)% and 
(83±11)%, respectively, P < 0.05] compared to the 
CON group. However, the up-regulated amplitude in 
the p-IκBα protein of the PTN+LPS group was small-
er than that of the LPS group (P < 0.05, Fig. 4B).
At 24 h, p-IκBα expression was also determined by 
Western blot analysis. Compared to the CON group 
[(48±23)%], there was no significant difference in 
the expression of cytoplasmic p-IκBα in the PTN and 
DMSO groups [(57±23)% and (60±22)%, respec-
tively]. Compared to the CON group [(48±23)%], 
however, the expression of p-IκBα was signifi-
cantly increased in the LPS and PTN+LPS groups 
[(100±35)% and (105±36)%, respectively, P < 0.05, 
Fig. 4C].
DISCUSSION
It is well known that NF-κB transcription factors 
are critical regulators of inflammation, innate and 
adaptive immunity, and the suppression of apopto-
sis[15]. In resting cells, NF-κB is present in the cytosol 
as an inactive heterodimer, mainly consisting of the 
p65/p50 subunits bound to the IκB inhibitor, which is 
rapidly degraded in response to stimuli such as bacte-
rial LPS, resulting in NF-κB nuclear entry[16]. There-
fore, we assessed cardiac NF-κB activation after an 
LPS challenge and determined whether the adminis-
tration of PTN, a selective NF-κB inhibitor, 6, 12 and 
24 h prior to this challenge could inhibit the effects. 
Our results indicate that myocardial NF-κB can be ac-
tivated following LPS administration, but PTN could 
block this effect completely when given 6 h and partly 
12 h prior to the LPS challenge, and did not block NF-
κB activation at 24 h. That means that PTN can block 
Fig. 3 The effect of PTN on myocardial IκBα levels in 
the presence or absence of LPS. A, B and C stand for the 
expression of IκBα at 6, 12 and 24 h after receiving intraperi-
toneally PTN, respectively. Data are shown as the mean±SD, 
with n = 6 in each group. GAPDH: glyceraldehyde-3-phosphate 
dehydrogenase; PTN: parthenolide; DMSO: dimethylsulfoxide; 
LPS: lipopolysaccharide.
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this activation when given within 24 h.
The activation of NF-κB is a key factor in exces-
sive inflammatory responses and inflammatory injury. 
LPS is a primary inducer of inflammatory responses 
through the biosynthesis and release of a variety of 
inflammatory mediators, which is involved in the im-
mune inflammatory response, leading to sepsis and 
septic shock[17]. Consistent with the theory that septic 
shock is a clinical syndrome with diverse etiologies, 
and NF-κB can be activated by a variety of bacteria, 
bacterial products and proinflammatory cytokines that 
are released during sepsis. NF-κB is the final target of 
these septic shock inducers[18].
NF-κB can be activated by numerous bacteria, bac-
terial toxins and proinflammatory mediators known 
to cause septic shock. LPS-induced activation of NF-
κB is biphasic: an early phase occurs at 0.5-2 h post 
stimulation, and a late phase occurs at 8-12 h post 
stimulation. LPS and other early inflammatory media-
tors cause the early phase of NF-κB activation, while 
TNF and IL-1β mediate the late phase[19]. The effects 
of bacterial toxins on NF-κB activity are dramatic 
and widespread, leading to massive elevation in NF-
κB activity in all organs studied to date[20-23]. This is 
consistent with the idea that multiple organs are in-
volved in septic shock. In the heart, cardiac-specific 
overexpression of IκBα protects against cardiac injury 
during trauma[24], and the inhibition of NF-κB activa-
tion prevents LPS-induced increase in microvascular 
permeability[23]. Cultured cells or animals developing 
a tolerance to endotoxin exhibited down-regulated 
NF-κB activity and reduced expression of NF-κB-
dependent genes when subsequently exposed to endo-
toxin[25]. This blunted NF-κB response is believed to 
be the result of increased IκBα[26], p50 or p52 expres-
sion or a switch from the formation of the p50/p65 
heterodimer to the p50/p50 homodimer[27]. Studies us-
ing promoter deletion mutagenesis and reporter gene 
analysis have demonstrated that NF-κB plays a crucial 
role in the LPS-activated promoter activity of over 
200 genes, many of which play important roles in the 
development of septic shock[28-30]. A major feature of 
the pathophysiology of septic shock is cardiovascular 
dysfunction; however, the inhibition of NF-κB activa-
tion corrects the cardiovascular functional abnormali-
ties seen in septic shock. Studies have demonstrated 
that cardiac-specific overexpression of IκBα prevents 
LPS-induced repression of cardiac systolic and di-
astolic function[31]. Furthermore, inhibition of the NF-
κB pathway can ameliorate the vascular derange-
ment in both LPS and polymicrobial models of septic 
shock[32,33].
The results of an endotoxemia study of jejunal mu-
cosa induced by LPS suggest that activated NF-κB 
consists primarily of p50 subunits. As an inhibitor of 
NF-κB, IκB has a variety of forms, mainly consist-
ing of IκBα and IκBβ. The main function of IκBα is 
to regulate and control the activation of NF-κB. IκBα 
demonstrates rapid degradation and resynthesis in re-
sponse to stimuli such as LPS and TNF-α and is re-
sponsible for the acute-phase activation of NF-κB. In 
contrast, IκBβ demonstrates delayed degradation and 
resynthesis and is responsible for the persistence of 
NF-κB activation[12]. This process requires the phos-
Fig. 4 Representative effect of PTN on myocardial 
p-IκBα levels in the presence or absence of LPS. A, B 
and C stand for the expression of p-IκBα at 6, 12 and 24 h after 
receiving intraperitoneally PTN, respectively. Data are shown 
as the mean±SD, with n = 6 in each group. GAPDH: glyc-
eraldehyde-3-phosphate dehydrogenase, PTN: parthenolide; 
DMSO: dimethylsulfoxide; LPS: lipopolysaccharide.
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phorylation of IκB by the IKK complex and the acti-
vation of NF-κB in response to proinflammatory stim-
uli and pathogen-associated molecular patterns[15,16]. 
In this study, therefore, we determined whether the 
model of septic shock was successful by measur-
ing the changes of NF-κB p50 and IκBα expression 
1 h after the administration of LPS. Our results show 
that the majority of NF-κB p50 is activated 1 h after 
the administration of LPS, inducing corresponding 
changes in the expression of IκBα and p-IκBα.
PTN has attracted considerable interest, and PTN-
containing products are commonly used to treat a 
variety of inflammatory conditions such as migraine, 
rheumatoid arthritis and asthma[34]. Several studies 
have reported that PTN inhibits NF-κB activation 
in cultured cells and experimental models[5-8,35]. Fur-
thermore, in vitro experiments with LPS-stimulated 
vascular smooth muscle cells and monocytes have 
shown that PTN at noncytotoxic doses inhibits IκBα 
degradation, preventing NF-κB activation and the 
subsequent gene expression. PTN also has beneficial 
effects during myocardial ischemia, endotoxic shock 
and renal disease through NF-κB inhibition[8]. Studies 
have found that PTN prevents NF-κB activation and 
dependent gene expression in both human and murine 
cells[36], and evidence indicates that PTN may inhibit 
the phosphorylation and degradation of IκBα[8], di-
rectly affect the DNA-binding ability of NF-κB with-
out changing IκBα degradation or block a signaling 
pathway other than NF-κB. Both the in vitro and in 
vivo anti-inflammatory effects of PTN have been as-
sociated with the inhibition of IκBα depletion, which 
in turn results in the inhibition of excessive activation 
of NF-κB[37]. Some studies have reported that PTN 
protects against myocardial ischemia and reperfusion 
injury in rats by selective inhibition of IKK activation 
and IκBα degradation[8]. In this study, the expression 
levels of NF-κB, IκBα and p-IκBα in the LPS group 
at 6 h were different from those in the PTN+LPS 
group, which means that PTN blocked the activation 
of NF-κB induced by LPS within 6 h. The expres-
sion levels of NF-κB, IκBα and p-IκBα in the LPS 
and PTN+LPS groups had a similar trend at 12 h, but 
amplitude was different between them, showing that 
PTN has a partial effect in blocking NF-κB activation. 
Inversely, the expression levels of NF-κB, IκBα and 
p-IκBα in the PTN+LPS group were similar to those 
in the LPS group and different from those in the PTN 
group when given at 24 h prior to LPS administration, 
which means that PTN did not block the activation of 
NF-κB induced by LPS at 24 h. From what has been 
discussed above, it would be reasonable to believe that 
PTN blocked the activation of NF-κB induced by LPS 
within 6 and 12 h, not at 24 h.
Our study has several potential limitations. We did 
not specifically investigate different doses of PTN in 
the pharmacological inhibition of NF-κB (500 μg/kg) 
for the second window of protection (SWOP)[8]. In 
addition, we focused on a single organ, the heart, at 
only a 1-h interval of LPS challenge. In future studies, 
we will design and execute a comprehensive approach 
to accomplish our original goal of determining the 
duration of PTN following in vivo administration.
In conclusion, myocardial NF-κB expression occurs 
1 h after the administration of LPS, and PTN, a selec-
tive inhibitor of NF-κB, could block this effect com-
pletely when given at 6 h, and partly block the activity 
12 h prior to the LPS challenge. There was no block 
after 24 h. This further indicates that PTN has no in-
hibitory effect 24 h after administration.  
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